| Ismail Qattash, MD | |
|
1 Memorial Sq Ste 2200, Greenfield, IN 46140-1378 | |
| (317) 468-6257 | |
| (317) 468-6268 |
| Full Name | Ismail Qattash |
|---|---|
| Gender | Male |
| Speciality | Nephrology |
| Experience | 23 Years |
| Location | 1 Memorial Sq Ste 2200, Greenfield, Indiana |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1538329982 | NPI | - | NPPES |
| 279500 | Other | IL | MEDICARE GROUP |
| 1538329982 1 | Medicaid | IL |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RN0300X | Internal Medicine - Nephrology | 036-120417 (Illinois) | Secondary |
| 207RN0300X | Internal Medicine - Nephrology | 01081966A (Indiana) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Osf Sacred Heart Medical Center | Danville, IL | Hospital |
| Hancock Regional Hospital | Greenfield, IN | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Sound Physicians Of Illinois Llc | 1557533734 | 202 |
| Hancock Physician Network, Llc | 8325952633 | 107 |
| Hancock Regional Hospital | 1850205162 | 45 |
| St Vincent Medical Group Inc | 7012047640 | 625 |
News Archive
Intellipharmaceutics International Inc. today announced that is has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration for a generic of Protonix® (delayed release pantoprazole sodium). Protonix inhibits gastric acid secretion and is prescribed for the short-term treatment of conditions such as stomach ulcers associated with gastroesophageal reflux disease as well as the long term treatment of pathological hypersecretory conditions including Zollinger-Ellison syndrome.
New research at Rhode Island Hospital has identified a treatment in animal models for glioblastomas - deadly brain tumors which, once diagnosed, offer a poor prognosis and relatively short life expectancy.
Trius Therapeutics, Inc. has announced that it initiated its first Phase 1 clinical trial of TR-701, an antibacterial drug candidate intended for treatment of patients with serious Gram-positive bacterial infections, including those caused by MRSA and other drug-resistant strains.
Researchers at the University of Oxford, Department of Psychiatry and NIHR Oxford Health Biomedical Research Centre, report the first large-scale evidence that COVID-19 survivors are at an increased risk of psychiatric disorders.
Obese women might be able to eliminate their increased risk for postmenopausal breast cancer by taking measures during perimenopause to prevent weight gain and to therapeutically control the metabolic effects of their obesity, according to the results of a preclinical study published in Cancer Research, a journal of the American Association for Cancer Research.
› Verified 8 days ago
| Entity Name | Sound Physicians Of Illinois Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1043598865 PECOS PAC ID: 1557533734 Enrollment ID: O20111012000272 |
News Archive
Intellipharmaceutics International Inc. today announced that is has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration for a generic of Protonix® (delayed release pantoprazole sodium). Protonix inhibits gastric acid secretion and is prescribed for the short-term treatment of conditions such as stomach ulcers associated with gastroesophageal reflux disease as well as the long term treatment of pathological hypersecretory conditions including Zollinger-Ellison syndrome.
New research at Rhode Island Hospital has identified a treatment in animal models for glioblastomas - deadly brain tumors which, once diagnosed, offer a poor prognosis and relatively short life expectancy.
Trius Therapeutics, Inc. has announced that it initiated its first Phase 1 clinical trial of TR-701, an antibacterial drug candidate intended for treatment of patients with serious Gram-positive bacterial infections, including those caused by MRSA and other drug-resistant strains.
Researchers at the University of Oxford, Department of Psychiatry and NIHR Oxford Health Biomedical Research Centre, report the first large-scale evidence that COVID-19 survivors are at an increased risk of psychiatric disorders.
Obese women might be able to eliminate their increased risk for postmenopausal breast cancer by taking measures during perimenopause to prevent weight gain and to therapeutically control the metabolic effects of their obesity, according to the results of a preclinical study published in Cancer Research, a journal of the American Association for Cancer Research.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Ismail Qattash, MD 1 Memorial Sq Ste 50, Greenfield, IN 46140-1357 Ph: (317) 468-6257 | Ismail Qattash, MD 1 Memorial Sq Ste 2200, Greenfield, IN 46140-1378 Ph: (317) 468-6257 |
News Archive
Intellipharmaceutics International Inc. today announced that is has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration for a generic of Protonix® (delayed release pantoprazole sodium). Protonix inhibits gastric acid secretion and is prescribed for the short-term treatment of conditions such as stomach ulcers associated with gastroesophageal reflux disease as well as the long term treatment of pathological hypersecretory conditions including Zollinger-Ellison syndrome.
New research at Rhode Island Hospital has identified a treatment in animal models for glioblastomas - deadly brain tumors which, once diagnosed, offer a poor prognosis and relatively short life expectancy.
Trius Therapeutics, Inc. has announced that it initiated its first Phase 1 clinical trial of TR-701, an antibacterial drug candidate intended for treatment of patients with serious Gram-positive bacterial infections, including those caused by MRSA and other drug-resistant strains.
Researchers at the University of Oxford, Department of Psychiatry and NIHR Oxford Health Biomedical Research Centre, report the first large-scale evidence that COVID-19 survivors are at an increased risk of psychiatric disorders.
Obese women might be able to eliminate their increased risk for postmenopausal breast cancer by taking measures during perimenopause to prevent weight gain and to therapeutically control the metabolic effects of their obesity, according to the results of a preclinical study published in Cancer Research, a journal of the American Association for Cancer Research.
› Verified 8 days ago
Kerri A. Kissell, MD Nephrology Medicare: Accepting Medicare Assignments Practice Location: 1 Memorial Sq Ste 2200, Greenfield, IN 46140 Phone: 317-462-6662 Fax: 317-468-6275 | |
Thomas L Whittaker, MD Nephrology Medicare: Not Enrolled in Medicare Practice Location: One Memorial Sq, Ste 50, Greenfield, IN 46140 Phone: 317-467-7100 Fax: 317-467-0209 | |
Thomas Jay Failinger, MD Nephrology Medicare: Accepting Medicare Assignments Practice Location: 300 E Boyd Ave Ste 201, Greenfield, IN 46140 Phone: 317-462-5112 | |
Charles R Taylor, MD Nephrology Medicare: Accepting Medicare Assignments Practice Location: 300 E Boyd Ave Ste 201, Greenfield, IN 46140 Phone: 317-462-5112 Fax: 317-462-5122 | |
Dr. Stephen J. Flink, M.D. Nephrology Medicare: Not Enrolled in Medicare Practice Location: 300 E Boyd Ave Ste 120, Greenfield, IN 46140 Phone: 317-462-3441 Fax: 317-477-6316 | |
Bryce S Lynn, MD Nephrology Medicare: Accepting Medicare Assignments Practice Location: 300 E Boyd Ave Ste 201, Greenfield, IN 46140 Phone: 317-462-5112 | |
Drew Dust, Nephrology Medicare: Accepting Medicare Assignments Practice Location: 1 Memorial Sq Ste 2200, Greenfield, IN 46140 Phone: 317-462-6662 Fax: 317-468-6275 |